| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO : 100 mg/mL (115.74 mM; Need ultrasonic) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis[1][2]. | [in vivo]
Bomedemstat treatment (oral gavage; 45 mg/kg; once daily; 56 d) normalizes or improves blood cell counts, reduces spleen volumes, restores normal splenic architecture, and reduces bone marrow fibrosis[1]. | Animal Model: | Mx-Jak2V617F mice[1] | | Dosage: | 45?mg/kg | | Administration: | Oral gavage; 45?mg/kg; once daily; 56 days | | Result: | Reduced splenomegaly significantly with a few treated mice normalizing their spleen weight, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination. |
| [IC 50]
KDM1/LSD1 | [storage]
4°C, away from moisture | [References]
[1] Jonas S Jutzi,et al. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone.
Hemasphere.2018 Jun 8;2(3):e54. DOI:10.1097/HS9.0000000000000054
[2] Yuan Fang, et al. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019 Dec 4;12(1):129. DOI:10.1186/s13045-019-0811-9 |
|
| Company Name: |
NewCan Biotech Limited
|
| Tel: |
+86-0571-86912261 +86-15658003402 |
| Website: |
https://www.newcanbio.com/ |
|